Schmuziger Nicolas, Gürtler Nicolas, Jungi Manuel, Gratwohl Alois, Probst Rudolf
Department of Otorhinolaryngology, University Hospital, Basel, Switzerland.
ORL J Otorhinolaryngol Relat Spec. 2004;66(3):105-10. doi: 10.1159/000079328.
Specific recommendations from the American Speech-Language Hearing Association (1994) exist for the audiometric surveillance of patients receiving aminoglycoside therapy. However, these recommendations are not based primarily on test-retest repeatability in often seriously ill patients. The probability of ototoxicity is very low during the first three days of aminoglycoside therapy, and significant threshold shifts can be assumed to represent a false-positive result. Baseline thresholds were measured in 28 patients before or not later than 24 h after the beginning of aminoglycoside therapy. These measurements were repeated in 22 patients during the first three days of the drug administration. Three out of 22 patients fulfilled the American Speech-Language-Hearing Association's (1994) criteria for cochleotoxicity making up a false-positive rate of 13%. In actual patients, the false-positive rate of audiometric surveillance during ototoxic drug administration may be substantially higher than in healthy subjects when these criteria are used.
美国言语语言听力协会(1994年)针对接受氨基糖苷类药物治疗患者的听力监测提出了具体建议。然而,这些建议并非主要基于对病情通常较重患者的重测重复性。在氨基糖苷类药物治疗的头三天,耳毒性的概率非常低,可认为显著的阈值变化代表假阳性结果。在28名患者中,于氨基糖苷类药物治疗开始前或开始后不超过24小时测量了基线阈值。在22名患者用药的头三天重复进行了这些测量。22名患者中有3名符合美国言语语言听力协会(1994年)的耳蜗毒性标准,假阳性率为13%。在实际患者中,使用这些标准时,耳毒性药物给药期间听力监测的假阳性率可能大大高于健康受试者。